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Percutaneous cardiopulmonary bypass (PCB) was 
hmtttuted in 30 initially stable patients who de- 
veloped either ctadiac arrest refractory to resus- 
citatton (n = 7) or cardiogenic shock (mean arts 
rial biood pressure cB0 mm Hg unresponsive to 
fluid resuscttation or vv) (n = 23) 
after a cat- ion laboratory complication. 
Events leadhrg to collapse included abrupt clo- 
sure during pe muaneous transkrminal coronary 
an~opiasty (P7CA) (n = 22), complications from 
dh#nostic cardiac catheterization (n = 6), left 
ventftcular perfo&ion duttng mitral valvule 
plasty (n q 1), and right ventricular perforation 
during pericardiocente& (n = 1). PCB was initi- 
ated within 20 minutes of cardiovascuiar col- 
lapse in 33% of patii (atvesk 21+ 13 minutes 
[range 10 to 501; and sho& 17 + 6 minutes 
[range 10 to 301). Mean arterial blood pressure 
i~onPCBfromOtoB6mmHginps 
tients with cardiac arrest and from 37 to 63 mm 
Hg in those with cardiogenic shock at mean PCB 
flow rates of 2.5 to 5.0 iiirs/min. Subsequent 
therapy on PCB included emergent cardiac 
surgery (n q 19, P7CA (II = 13) and medial ther- 
spy (n q 3). Six patients (20%) survived to hospi- 
tal dischar@ (3 with cardiac sur@ry, 2 with 
PTCA, and 1 with medical therapy). All 7 patients 
with refractory cardiac arrest died despite fur- 
ther interventions on PCB, whereas 6 of 23 
(26%) with cardiogenic shock survived to hospi- 
tal discharge. Thus, in response to cardiovascu- 
lar collapse in the catheterization laboratory, 
PCB does not salvage patients who do not r-e= 
gain a stabte cardiac rhythm. PCB can stabilize 
patients who develop cardiogenic shock for fur- 
ther interventions whi& are Bfesaving in only a 
minoftty of patients. 
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P ercutaneous cardiopulmonary bypass (PCB) has been used in the cardiac catheterization laboratory to provide prophylactic support during percuta- 
neous transluminal coronary angioplasty (PTCA) in pa- 
tients with severe left ventricular dysfunction (left ven- 
tricular ejection fraction ~25%) or during PTCA of a 
target vessel supplying >50% of the remaining viable 
myocardium.‘,* PCB has also been used as a temporary 
emergency support measure in patients sustaining car- 
diovascular collapse from acute myocardial infarction, 
pulmonaty embolism, trauma, drug overdose, unsuc- 
cessful PTCA, postoperative deterioration and aortic 
stenosis, and after rupture of aortic dissection.34 Two 
previous small studies suggested that the use of PCB in 
patients with cardiac arrest improved resuscitative ef- 
forts.4,6 However, the mechanism for this improvement 
is not clear, because direct myocardial perfusion does not 
occur while patients are on PCB, and regional myocar- 
dial ischemia has been shown when PCB is used in those 
with coronary artery disease.7 Therefore, we reviewed 
our experience with emergent PCB in patients develop- 
ing refractory cardiac arrest or cardiogenic shock in the 
cardiac catheterization laboratory from a procedural re- 
lated complication to further examine the use of this 
technology. 
METHODS 
Study patients: A retrospective review was per- 
formed of the use of emergent PCB for cardiovascular 
collapse occurring in the cardiac catheterization labora- 
tories of the University of Michigan and William Beau- 
mont Hospitals. Between January 1988 and January 
1992, 30 patients were identified who presented to the 
cardiac catheterization laboratory with stable hemody- 
namics and had PCB initiated emergently for either re- 
fractory cardiac arrest or cardiogenic shock occurring as 
a result of a catheterization laboratory complication. Pa- 
tients were considered to have refractory cardiac arrest 
only if aggressive attempts at resuscitation were unsuc- 
cessful in establishing a stable cardiac rhythm. Patients 
were placed on PCB for cardiogenic shock if hypoten- 
sion and peripheral hypoperfusion persisted despite ag- 
gressive fluid replacement and inotropic support. 
Technique of percutaneous cardiopulmonary by 
pass: A portable PCB system (C.R. Bard, Inc., Biller- 
ica, Massachusetts) was used, and included a centrifu- 
gal nonocclusive pump with a hollow-fiber membrane 
oxygenator and water-based heat exchanger. Femoral ar- 
terial and venous access were obtained contralateral to 
the site of cardiac catheterization. Over a 0.035inch 
guidewire, progressive dilatation of the femoral artery 
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r 1 TABLE I Clinical Characteristics 
Refractory Cardiogenic 
Cardiac Arrest Shock 
Patients 7 23 
Age (years) 572 11 63 + 6 
Men 3 (43%) 14 (61%) 
Risk factors 
Hypertension 6 (86%) 16 (70%) 
Diabetes 2 (29%) 3 (13%) 
Smoking 1(15%) 6 (26%) 
Hypercholesterolemia 1 (15%) 7 (34%) 
Previous events 
Myocardial infarction 4 (57%) 10 (44%) 
Coronary angroplasty 1(15%) 3 (13%) 
Coronary bypass surgery 1(15%) 5 (22%) 
Angina class 3-4 5 (72%) 20 (87%) 
Congestive heart failure class 3-4 2 (29%) 3 (13%) 
Left ventricular ejection fraction (%) 46 + 20 43 + 14 
Number of arteries narrowed > 50% 
in diameter 
0 1(15%) 1(5%) 
1 2 (29%) 5 (22%) 
2 1(15%) 7 (30%) 
3 3 (42%) 10 (43%) 
Left main 0 6 (23%) 
was performed before insertion of an 18Fr cannula. An 
18Fr multihole femoral venous cannula was inserted by 
a similar technique, and was positioned with fluoroscopy 
at the junction of the inferior vena cava and right atrium. 
Intravenous heparin was administered to maintain an ac- 
tivated clotting time of >400 seconds throughout the pro- 
cedure. The cannula system was connected to the 
portable PCB in a manner to ensure an air-free system. 
PCB was initiated at 2 liters of flow/min and was in- 
creased until the mean arterial blood pressure was >60 
mm Hg or further increases in flow were limited by in- 
adequate venous return. The pulmonary capillary wedge 
pressure was maintained at >lO mm Hg to ensure unim- 
peded venous return at higher flow rates. Periodic mon- 
itoring of arterial blood gases, pulmonary capillary 
wedge pressures, electrocardiograms, coagulation vari- 
ables, electrolytes and mixed venous oxygen saturations 
was performed. 
Termination of percutaneous cardiopulmonary 
bypass: Patients achieving hemodynamic stability in the 
catheterization laboratory had PCB gradually weaned 
over 10 to 15 minutes, with an intraaortic balloon pump 
and inotropic agent support used as necessary. These pa- 
tients were then sent for surgical removal of the cannula 
system. Patients having cardiac surgery were transported 
to the operating room on PCB and had PCB terminated 
after standard cardiopulmonary bypass was established. 
RESULTS 
Patient charecteristks: Clinical and angiographic 
characteristics of patients are listed in Table I. Seven pa- 
tients were placed on PCB because of refractory cardiac 
arrest and 23 because of cardiogenic shock. Of patients 
in cardiogenic shock, 16 (70%) initially had cardiac ar- 
rest (mean duration 13 minutes [range 3 to 451) and were 
successfully resuscitated before the initiation of PCB. 
Events leading to cardiovascular collapse: Abrupt 
closure during PTCA was the most frequent cause of 
TABLE II Details of Emergent Percutaneous Cardiopulmonary 
Bypass 
Refractory Cardiogenic 
Cardiac Shock P 
Arrest (n = 7) (n = 23) Value 
Time to initiation of bypass (min) 21 + 13 17?6 NS 
Duration of bypass (min) 40 + 22 165 + 213 0.2 
Mean arterial blood pressure on 56 e 7 63 + 9 NS 
bypass (mm Hg) 
cardiovascular collapse needing PCB support (n = 22). 
Severe left main coronary artery disease was present in 
5 patients needing PCB because of complications from 
diagnostic cardiac catheterization, whereas an additional 
one with 3-vessel coronary artery disease developed re- 
fractory cardiac arrest after contrast injection of the right 
coronary artery and was placed on PCB. Left ventricular 
perforation during mitral valvuloplasty, and right ven- 
tricular laceration with cardiac tamponade at pericar- 
diocentesis were other catheterization laboratory com- 
plications for which emergent PCB was instituted. 
Percutaneous cardiopulmonary support: PCB was 
initiated within 20 minutes of cardiovascular collapse in 
25 of 30 patients (83%) (Table II). The mean arterial 
blood pressure for patients in refractory cardiac arrest 
on PCB increased from 0 to 56 mm Hg at flow rates of 
3 to 5 liters/min. No patient in the refractory cardiac ar- 
rest group regained consciousness while on PCB. Mean 
arterial blood pressure in patients in cardiogenic shock 
on PCB increased from 37 to 63 mm Hg at flow rates 
of 2.5 to 5.0 liters/min. 
Treatment after initiation of percuteneous cardict 
pulmonary bypass: After PCB was established, 14 pa- 
tients were sent for emergent cardiac surgery, 13 had re- 
peat PTCA, and 3 were not considered candidates for 
revascularization and were managed medically. Six pa- 
tients (20%) survived to hospital discharge. All 7 pa- 
tients with refractory cardiac arrest died despite further 
interventions on PCB. Emergent cardiac surgery was 
performed in 3 patients (2 coronary artery bypass graft 
procedures and 1 repair of right ventricular laceration); 
however, none were able to be weaned from PCB after 
surgery. Repeat PTCA was performed on PCB in 4 pa- 
tients, but none regained a stable cardiac rhythm after 
PICA and all died in the cardiac catheterization labo- 
ratory. 
Of patients having PCB for cardiogenic shock, 13 of 
23 (57%) survived 24 hours after the initial intervention 
on PCB and were successfully weaned from PCB, but 
only 6 (26%) were discharged eventually from the hos- 
pital. Subsequent deaths in early surviving patients were 
due to refractory congestive heart failure (n = 4), sepsis 
(n = 2) and multisystem failure (n = 1). The surgical in- 
terventions in patients with cardiogenic shock included 
coronary artery bypass grafting (n = 9), repair of left 
ventricular perforation (n = l), and orthotopic cardiac 
transplantation (n = 1) after 2 days on an extracorporeal 
membrane oxygenation system. Surgical patients sur- 
viving to hospital discharge included 2 who underwent 
coronary artery bypass grafting, and 1 who had cardiac 
transplantation. Repeat PTCA on PCB was performed 
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TABLE III Percutaneous Cardiopulmonary Bypass for 
“Refractory” Cardiac Arrest 
Number Early Surviving 
Study of Patients Patients Discharged 
Baird et all2 19 3 3 (16%) 
Mattox and Beall 43 17 (40%) 
Phillips et all3 5 3 (60%) 
Reichman et al3 36 18 6 (17%) 
Shawl et al4 7 6 4 (57%) 
Mooney et al6 11 7 (64%) 
Present study 7 0 0 
Total 128 40 (31%) 
in 9 patients. PTCA was successful in 7 patients; 6 were 
weaned from PCB before leaving the catheterization lab- 
oratory, with 2 eventually surviving to hospital discharge. 
Three patients with cardiogenic shock were not consid- 
ered candidates for surgery or PTCA; intraaortic balloon 
counterpulsation with inotropic agent support enabled 2 
of these to be weaned from PCB, and 1 survived to hos- 
pital discharge. 
Compkatiis: Most PCB-related complications 
were related to cannula insertion sites. Bleeding need- 
ing transfusion occurred in 8 patients. A femoral artery 
thrombosis developed in 1 patient after sheath removal, 
and 2 needed surgical repair of femoral artery fistulae. 
Follow-up: The mean hospital stay in the 6 patients 
surviving to discharge was 22 days (range 6 to 62). Fol- 
low-up was available in 5 patients at a mean of 18 weeks. 
Four patients were free of cardiac symptoms, and 1 was 
being managed medically for recurrent stable angina. 
DISCUSSION 
Percutaneous cardiopulmonary bypass was advo- 
cated recently for prophylactic use in high-risk PTCA’ 
and for emergency use in sudden cardiovascular col- 
lapse.2-6 In contrast to the intraaortic balloon pump, PCB 
can maintain hemodynamic stability in the absence of 
an intrinsic cardiac rhythm or effective cardiac output 
and can improve tissue perfusion in cases of severe left 
ventricular failure; it cannot be used in patients with ile- 
ofemoral disease nor for >24 hours, because of disrup- 
tion of blood elements. 
The rationale for use of PCB in patients with car- 
diovascular collapse is to provide temporary hemody- 
namic support for subsequent percutaneous or surgical 
intervention. Rapid initiation of PCB within 20 minutes 
of cardiovascular collapse appears necessary if subse- 
quent interventions are to prove successful in achieving 
hemodynamic stability.’ The ability to rapidly place a 
patient on PCB in the catheterization laboratory suggests 
that PCB could help salvage a large number of patients 
with cardiovascular collapse from catheterization labo- 
ratory complications. However, several studies suggest 
that whereas PCB supports the peripheral circulation, 
coronary blood flow is not maintained and actually de- 
creases when PCB is initiated.7 This decrease in coro- 
nary blood flow has been hypothesized to be a result of 
coronary steal8 or impaired autoregulation of the cardiac 
microcirculation from nonpulsatile flo~.~ Pavlides et al7 
have shown that regional and global left ventricular dys- 
function occur with PTCA balloon inflation during PCB 
despite reductions in measured afterload and maximal 
oxygen consumption requirements. Myocardial regions 
supplied by stenotic vessels had deterioration of wall 
motion when patients were placed on PCB before bal- 
loon inflation and had further deterioration with balloon 
inflation. Thus, whereas cerebral, renal and hepatic blood 
flow are maintained on PCB during cardiovascular col- 
lapse, coronary blood flow is not equally preserved, and 
progressive myocardial ischemia occurs in patients with 
coronary artery disease. Resuscitation from refractory 
cardiac arrest on PCB would be more difficult owing to 
this progressive ischemia. 
We found PCB to be useful in stabilizing patients in 
cardiogenic shock as a result of a catheterization labo- 
ratory complication, including patients initially present- 
ing with cardiac arrest who were successfully resusci- 
tated to a stable rhythm before PCB initiation. However, 
we did not find use for this technique in patients with 
refractory cardiac arrest. No patient with refractory car- 
diac arrest in this study was salvaged with the use of 
PCB, although 6 of 7 were placed on PCB within 20 
minutes of arrest. 
Early studies of animals suggested that cardiopul- 
monary bypass could successfully facilitate defibrillation 
in dogs with intractable ventricular fibrillationloJi; how- 
ever, its usefulness in refractory cardiac arrest in humans 
is controversial.3*4Jj,12,13 Table III reviews the results of 
studies that evaluated the use of emergent PCB in car- 
diac arrest. Survival rates ranged from 16 to 64%. Events 
preceding cardiac arrest and location within the hospital 
when PCB was initiated widely varied between studies. 
In the study by Baird et al,12 PCB was begun for cardiac 
arrest in patients presenting to the hospital with acute my- 
ocardial infarction. In other studies, PCB was initiated 
for cardiac arrest occurring as a complication of several 
medical conditions including trauma, sepsis, drug over- 
dose, pulmonary embolism, myocardial infarction, car- 
diomyopathy and postoperative collapse.3J3J4 PCB was 
initiated in many different hospital locations ranging from 
the emergency room to the intensive care unit. Many of 
the aforementioned studies did not specify the specific 
etiology of the cardiac arrest, the duration of the arrest 
nor the extent of the resuscitative efforts performed be- 
fore initiation of PCB. 
Shawl et al4 and Mooney et al6 were the Iirst to ex- 
amine PCB for cardiac arrest occurring in, or in prox- 
imity to, the catheterization laboratory and reported the 
highest late survival rates for this technique. However, 
the extent of resuscitative efforts before initiating PCB 
was not discussed. Previous studies reporting a high suc- 
cess of PCB in reversing refractory cardiac arrest may 
have included patients who would have regained stable 
cardiac rhythm with more persistent resuscitation alone. 
In the present study, 23 of 30 patients placed on PCB 
had cardiac arrest, but 16 of these regained a stable car- 
diac rhythm during resuscitation before initiation of 
PCB. Thirty percent of the resuscitated patients survived 
to hospital discharge, while none of the 7 with refrac- 
tory cardiac arrest survived despite PCB. 
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Study limitations: The retrospective nature of this 
investigation, together with the small study size, limits 
generalization of the findings. All patients developed car- 
diovascular collapse after a cardiac catheterization lab- 
oratory complication, and thus the use of PCB in car- 
diovascular collapse from other etiologies cannot be 
extrapolated. 
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